CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD).

芝加哥-（商业新闻）-今天，全球领先的医疗技术、药物诊断和数字解决方案创新者GE HealthCare（纳斯达克：GEHC）和领先的心脏成像软件公司Medis medical Imaging宣布了他们的合作，旨在帮助推进冠状动脉疾病（CAD）诊断和治疗中的精准护理。

Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform. The collaboration seeks to provide access to emerging technologies, like Medis QFR, while also reducing complexity in the cath lab to improve the operating environment for clinicians..

两家公司将共同致力于进一步开发和商业化Medis定量流量比（Medis QFR），这是一种非侵入性的冠状动脉生理评估方法，是GE HealthCare围绕Allia平台构建的介入心脏病学组合的一部分。该合作旨在提供对Medis QFR等新兴技术的访问，同时降低cath实验室的复杂性，以改善临床医生的操作环境。。

Within the complex umbrella of cardiovascular disease, CAD is a type of heart disease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart. The impact of this narrowing can ultimately result in angina (chest pain), which has been shown to double the risk of major cardiovascular events,1 as well as myocardial infarction (heart attack) or even death.

在复杂的心血管疾病中，CAD是一种心脏病，当冠状动脉狭窄且心脏无法向心脏输送足够的富氧血液时会发展。这种狭窄的影响最终可能导致心绞痛（胸痛），这已被证明会使主要心血管事件1以及心肌梗塞（心脏病发作）甚至死亡的风险增加一倍。

In order to accurately diagnose suspected CAD, a significant percentage of patients can undergo invasive coronary angiography to help clinicians determine the severity of their disease. Traditionally, a clinician will then visually interpret an angiogram to determine whether a patient requires treatment, such as a percutaneous coronary intervention (PCI), as well as determine where, or which lesion, to treat to restore blood flow..

为了准确诊断疑似CAD，相当一部分患者可以进行有创冠状动脉造影，以帮助临床医生确定疾病的严重程度。传统上，临床医生会直观地解释血管造影，以确定患者是否需要治疗，例如经皮冠状动脉介入治疗（PCI），以及确定在哪里或哪个病变需要治疗以恢复血流。。

As part of GE HealthCare’s commitment to advancing precision care in interventional cardiology, the company’s collaboration with Medis Medical Imaging will bring Medis QFR to clinicians as an emerging, non-invasive, image-based diagnostic approach to the assessment of coronary artery physiology and the treatment of CAD.

作为GE HealthCare致力于推进介入心脏病学精准护理的一部分，该公司与Medis Medical Imaging的合作将为临床医生带来Medis QFR，作为一种新兴的，非侵入性的，基于图像的诊断方法，用于评估冠状动脉生理学和CAD治疗。

The benefits of QFR guidance are supported in a recent study that showed that a QFR-guided strategy of lesion selection for PCI improved two-year clinical outcomes, including reduction in myocardial infraction and ischemia-driven revascularization, when compared with standard angiography guidance alone.2.

QFR指导的益处在最近的一项研究中得到了支持，该研究表明，与单独的标准血管造影指导相比，QFR指导的PCI病变选择策略改善了两年的临床结果，包括减少心肌梗塞和缺血驱动的血运重建。

“We continue to see an evolution in how clinicians work to treat cardiovascular disease and want to give clinicians the tools, along with the flexibility and adaptability, they need to enable better outcomes for their patients,” says Arnaud Marie – General Manager for Global Intervention at GE HealthCare.

GE HealthCare全球干预总经理Arnaud Marie表示：“我们继续看到临床医生治疗心血管疾病的方式发生了变化，并希望为临床医生提供工具，以及灵活性和适应性，以便为患者带来更好的结果。”。

“In the assessment of coronary artery disease, QFR represents a significant advancement in how efficiently it can provide critical insights. We’re excited to collaborate with Medis Medical Imaging to add innovative, non-invasive, image-based QFR to our portfolio of offerings around our Allia IGS platform to streamline the experience for clinicians and help us to deliver on our vision for the future image-guided therapy.”.

“在冠状动脉疾病的评估中，QFR在提供关键见解的效率方面取得了重大进步。我们很高兴与Medis Medical Imaging合作，将创新的，非侵入性的，基于图像的QFR添加到我们围绕Allia IGS平台的产品组合中，以简化临床医生的经验，并帮助我们实现未来图像引导治疗的愿景。”。

Medis Medical Imaging has been developing innovative post-processing software for the quantification of cardiovascular images for thirty-five years. Medis’ QFR is a proprietary solution that delivers image-based physiology of coronary obstructions based on angiography imaging analysis alone. Interventional cardiologists can seamlessly adopt the solution into their clinical workflow to help them effectively and efficiently determine if a PCI is required to treat the patient or if treatment should be deferred for ongoing monitoring or other alternative treatment options.

35年来，Medis Medical Imaging一直在开发用于量化心血管图像的创新后处理软件。Medis的QFR是一种专有解决方案，仅基于血管造影成像分析即可提供基于图像的冠状动脉阻塞生理学。介入心脏病专家可以无缝地将该解决方案纳入其临床工作流程，以帮助他们有效地确定是否需要PCI治疗患者，或者是否应将治疗推迟至持续监测或其他替代治疗方案。

If treatment is needed, Medis’ QFR technology can help clinicians select the ultimate lesion(s) for treatment and create the right treatment plan for a balloon or stent-based PCI procedure, while also helping the clinician evaluate the efficacy of that treatment. This analysis can be performed in real time while the patient is on the table and results are displayed on the large display monitor in the cath lab..

如果需要治疗，Medis的QFR技术可以帮助临床医生选择最终病变进行治疗，并为基于球囊或支架的PCI手术制定正确的治疗计划，同时还可以帮助临床医生评估该治疗的疗效。该分析可以在患者躺在桌子上时实时进行，结果显示在cath实验室的大显示屏上。。

“We are absolutely delighted to be taking this next step with GE HealthCare, a fellow leader in the interventional cardiology domain,” shares Maya Barley, CEO Medis Medical Imaging. “Building on Medis QFR’s decade of AI research, customer-focused product development, clinical evidence generation and business development, we are excited to be able to further accelerate our efforts around Medis QFR to enable more hospitals and clinicians to apply physiology in day-to-day interventional practice a part of best-practice clinical care – making this technology more accessible and available to patients than ever before.”.

“我们非常高兴能与介入心脏病学领域的领导者GE HealthCare一起迈出下一步，”Medis Medical Imaging首席执行官玛雅·大麦（Maya Barley）分享道。“在Medis QFR十年的人工智能研究、以客户为中心的产品开发、临床证据生成和业务开发的基础上，我们很高兴能够进一步加速我们围绕Medis QFR的努力，使更多的医院和临床医生能够在日常介入实践中应用生理学，这是最佳实践临床护理的一部分-使这项技术比以往任何时候都更容易获得和可用。”。

Innovative technologies like Medis QFR enhance GE HealthCare’s comprehensive portfolio of interventional cardiology solutions built around the Allia Platform designed to optimize workflows, unlock efficiencies, and drive better patient outcomes in the treatment of cardiovascular disease.

Medis QFR等创新技术增强了GE HealthCare围绕Allia平台构建的介入心脏病学解决方案的综合组合，该平台旨在优化工作流程，提高效率，并推动心血管疾病治疗取得更好的患者预后。

To learn more about GE HealthCare’s latest innovations in interventional cardiology including Allia IGS Pulse, the next generation of image-guided systems for cardiac imaging, or Medis QFR, please visit the EuroPCR 2024 congress booth #F15 in Paris, France from May 14 – 17 or visit the website here..

要了解更多有关GE HealthCare在介入心脏病学方面的最新创新，包括Allia IGS Pulse（下一代心脏成像图像引导系统）或Medis QFR，请于5月14日至17日访问位于法国巴黎的EuroPCR 2024 congress booth#F15或访问此处的网站。。

About GE HealthCare Technologies Inc.

关于GE HealthCare Technologies Inc。

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.

GE HealthCare是全球领先的医疗技术、药物诊断和数字解决方案创新者，致力于提供集成的解决方案、服务和数据分析，使医院更高效、临床医生更有效、治疗更精确，患者更健康、更快乐。

Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring.

GE HealthCare为患者和提供者服务了125多年，正在推进个性化、互联化和富有同情心的护理，同时简化患者跨越护理路径的旅程。我们的成像、超声、患者护理解决方案和药物诊断业务共同帮助改善患者护理，从诊断到治疗再到监测。

We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits..

我们是一家价值196亿美元的企业，拥有约51000名员工，致力于创造一个医疗保健无限的世界。。

About Medis Medical Imaging

关于Medis Medical Imaging

For over 35 years, Medis has been providing high-quality quantitative analysis solutions for cardiovascular imaging to the medical community. Our heritage and core values are based on this strong purpose of contributing to a healthier society by providing the right tools to clinicians worldwide. Medis’ software is internationally appreciated due to its ease of use and its clinical outcome for the patients.

35多年来，Medis一直为医学界提供高质量的心血管成像定量分析解决方案。我们的传统和核心价值观基于这样一个强大的目标，即通过为全世界的临床医生提供正确的工具，为更健康的社会做出贡献。Medis的软件因其易用性及其对患者的临床效果而受到国际认可。

At Medis, quality is key, all our products are developed and validated extensively to guarantee the highest quality, without compromise. We continuously focus on the creation of clinically relevant innovative software solutions in the cardiovascular imaging domain..

在Medis，质量是关键，我们所有的产品都经过广泛的开发和验证，以确保最高的质量，不妥协。我们一直专注于在心血管成像领域创建临床相关的创新软件解决方案。。